Treating central nervous system lymphoma in the era of precision medicine

Garcilazo-Reyes, Ytel; Ibáñez-Juliá, María-José; Hernández-Verdin, Isaias; Nguyen-Them, Ludovic; Houillier, Caroline; Hoang-Xuân, Khê; Alentorn, Agustí

doi:10.1080/23808993.2020.1777853

Cited by 1 publication

(1 citation statement)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recognized as mature post-germinal B cells (ABC subtype like), the central nervous system (CNS) DLBCL represents only ≤1% of all lymphomas and approximately 2% of all primary CNS tumors; furthermore, 95% of tumors have a comparative histology with systemic DLBCL [ 67 , 75 ]. Since the blood brain barrier impedes R-CHOP treatment, high dose methotrexate (HD-MTX, >3 g/m 2 ) based regimens are the gold standard for PCNSL patients resulting in a five year survival rate of 30% and high risk of clinical neurotoxicity specially in patients > 60 [ 68 , 76 ]. Furthermore, PCNSL is less frequently associated with any atopic disorder (OR = 0.54, 95% CI = 0.33 to 0.87), but it is strongly associated with a family history of NHL (OR = 4.11, 95% CI = 1.58 to 10.66) and less clearly with lifetime cigarette exposure (OR = 1.51, 95% CI = 0.83 to 2.74, for 1–10 pack-years vs. nonsmoker) [ 30 ].…”

Section: Gwas In B-cell Nhlmentioning

confidence: 99%

Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin’s Lymphomas from Genome-Wide Association Studies

Hernández-Verdin¹,

Labreche²,

Benazra

et al. 2020

IJMS

Self Cite

View full text Add to dashboard Cite

B-cell non-Hodgkin’s lymphoma (NHL) risk associations had been mainly attributed to family history of the disease, inflammation, and immune components including human leukocyte antigen (HLA) genetic variations. Nevertheless, a broad range of genome-wide association studies (GWAS) have shed light into the identification of several genetic variants presumptively associated with B-cell NHL etiologies, survival or shared genetic risk with other diseases. The present review aims to overview HLA structure and diversity and summarize the evidence of genetic variations, by GWAS, on five NHL subtypes (diffuse large B-cell lymphoma DLBCL, follicular lymphoma FL, chronic lymphocytic leukemia CLL, marginal zone lymphoma MZL, and primary central nervous system lymphoma PCNSL). Evidence indicates that the HLA zygosity status in B-cell NHL might promote immune escape and that genome-wide significance variants can give biological insight but also potential therapeutic markers such as WEE1 in DLBCL. However, additional studies are needed, especially for non-DLBCL, to replicate the associations found to date.

show abstract